Evidence map›Paper›PMID 41892949›Full record

ArticleMarine drugs2026

Discovery of Marine-Inspired Guanidine-Based PDE4 Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease.

Xinglong Dai, Jie Hao, Yan Zhang, Yaping Yang, Wanli Meng, Fang Lu, Jianchun Zhao, Guanhua Du, Shengbiao Wan, Jiejie Hao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Marine drugs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xinglong DaiLaboratory for Marine Drugs and Bioproducts, Qingdao Marine Science and Technology Center, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China.
Jie HaoLaboratory for Marine Drugs and Bioproducts, Qingdao Marine Science and Technology Center, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China.
Yan ZhangLaboratory for Marine Drugs and Bioproducts, Qingdao Marine Science and Technology Center, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China.
Yaping YangLaboratory for Marine Drugs and Bioproducts, Qingdao Marine Science and Technology Center, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China.
Wanli MengLaboratory for Marine Drugs and Bioproducts, Qingdao Marine Science and Technology Center, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China.
Fang LuLaboratory for Marine Drugs and Bioproducts, Qingdao Marine Science and Technology Center, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China.
Jianchun ZhaoMarine Biomedical Research Institute of Qingdao, Qingdao 266003, China.ORCID 0000-0002-1223-618X
Guanhua DuMarine Biomedical Research Institute of Qingdao, Qingdao 266003, China.
Shengbiao WanLaboratory for Marine Drugs and Bioproducts, Qingdao Marine Science and Technology Center, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China.
Jiejie HaoLaboratory for Marine Drugs and Bioproducts, Qingdao Marine Science and Technology Center, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China.

Funding

National Nature Science Foundation of China 82574314Shandong Provincial Key Research and Development Program 2023CXPT092Special funds of Shandong Province for Qingdao National Laboratory of Marine Science and Technology 2022QNLM030003
6 · The paper itself

Abstract

Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory respiratory disorder with a globally increasing prevalence. Current therapeutic strategies are limited by drug resistance and safety concerns. Studies suggest that inhibiting the secretion of inflammatory cytokines represents a promising approach for COPD treatment. Phosphodiesterase-4 (PDE4) inhibitors have emerged as potent anti-inflammatory agents for respiratory diseases. In this study, we integrated a marine-derived natural product with computer-aided drug design to develop 32 novel PDE4 inhibitors. Compound

Indexed as

Anti-Inflammatory AgentsAquatic OrganismsPhosphodiesterase 4 InhibitorsPulmonary Disease, Chronic ObstructiveAnimalsCyclic Nucleotide Phosphodiesterases, Type 4CytokinesDisease Models, AnimalDrug DiscoveryHumansLungMaleMiceNF-kappa BRatsRAW 264.7 CellsAnti-Inflammatory AgentsCyclic Nucleotide Phosphodiesterases, Type 4CytokinesNF-kappa BPhosphodiesterase 4 Inhibitorsanti-inflammatorycAMP-PKA-CREBCOPDPDE4 inhibitor

Identifiers

PMID41892949
PMCPMC13028064

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.